Thetis is developing a potential first-in-class, safe, oral therapy for the treatment of inflammatory bowel disease (IBD), a set of chronic, relapsing gastrointestinal inflammatory disorders that includes ulcerative colitis and Crohn’s Disease.
Thetis’ lead candidate, TP-317, is a new molecular entity that delivers Resolvin E1 (RvE1), an endogenous lipid mediator that resolves inflammation and promotes mucosal healing without compromising immune function. Enabled by Thetis’ proprietary HEALER technology, TP-317 is a proprietary, stable salt of RvE1 that has been shown to modulate multiple inflammatory processes associated with IBD pathogenesis including immune cell infiltration, proinflammatory cytokine expression, maintenance of epithelial barrier integrity, and immunological tolerance.
Given its unique mechanism of action and anticipated product profile, TP-317 is positioned as a safe, oral therapy for induction and maintenance of remission of IBD patients before they escalate to biologics and other immunosuppressive agents. Thetis was recently awarded a $2.3 million Fast Track NIH grant supporting TP-317 development and is targeting the initiation of clinical studies in 2020.